►
From YouTube: Open Source Antibiotics Science Update Jan 15 2021
Description
Weekly open project meeting for Open Source Antibiotics Series 2.
Full Project: https://github.com/opensourceantibiotics/Series-2-Diarylimidazoles
Relevant GitHub Issue: https://github.com/opensourceantibiotics/Series-2-Diarylimidazoles/issues/51
On the call: Professor Matthew Todd, Dr Dana Klug, Giada Sabatino (UCL), Dr Chris Swain (Cambridge MedChem Consulting), Anthony Sama (citizen contributor), Lori Ferrins (Northeastern University)
A
Okay,
all
right
opens
up
anybody's
series
two
friday
january
15th.
I
was
just
saying
that
then
they're
recording
the
last
time
I've
uploaded.
Now
I
was
looking
back
through
it
because
there
were
an
awful
lot
of
really
good
suggestions
for
for
molecules,
and
I
started
to
try
to
capture
this,
but
I
just
run
out
of
time,
and
so
I'm
gonna
put
this
on
someone.
A
Is
that
all
right?
So
that's
the
meeting
yeah,
so
the
I
was
just.
I
went
through
the
yeah,
listen
to
the
meeting
again
and
there
were
a
huge
number
of
really
good
suggestions
here
from
everybody,
particularly
ones
where
we
were
talking
about
structures
that
we
could
make
as
feedstocks
to
allow.
You
know
diverse
syntheses
of
other
molecules
and
alternative
cores.
A
B
A
B
Yeah,
the
paradise
substitute
depends
on
middle.
They
were
doing
things
a
bit
differently.
They
were
using
some
sort
of
click
reaction.
They
tested
them
with
them
without
a
metal
insert
and
they
found
the
ones
without
the
metal
were
better.
I
couldn't
get
the
full
paper,
but
it's
on
the
wiki.
If
anyone
wants
to
try
and
log
in
with
their
credentials
great.
A
A
There
were
some
other
things
here
in
terms
of
if
we
wanted
to
try
and
explore
this
amino
substitution
that
we
were
talking
about
last
time
or
something
polar
that
I
wasn't
sure
so
danny
you
posted
that
very
nice
topless
analysis
that
you
did
and
the
suggestion
there
were.
I
I
don't
think
it
suggested
that
we
should
be
putting
things
like
amy's
in
that
position.
From
what
you
had
we
went.
You
were
trying
to
align
it
with
one
particular.
A
A
E
A
A
E
C
A
D
A
B
A
A
F
A
F
A
Okay,
all
right
great
we're
gonna
we're
gonna,
stick
that
on
the
list
right,
there's
a
specific
which
is
good.
Sorry,
I'm
just
trying
to
get
back
to
where
the
other
picture
was
so
just
I
think
the
other
thing
as
well
that
we
needed
to
fix
in
the
planning.
Besides
how
well,
besides,
you
know,
buying
some
of
the
starting
material
and
looking
at
whether
we
could
get
this,
which
was
the
other
call
that
you
suggested
laurie.
E
A
C
A
A
All
right
I
mean
the
other
things
here
are
just
fairly
quick.
I
guess
there's
been
no
chemistry
updates
because
of
course,
we've
been
away
and-
and
the
lab
is
still
closed-ish
at
the
moment
until
ed
and
danny
can
get
back
in.
So
we
haven't
got
a
lot
of
chemistry
stuff
to
do,
but
of
course
we
can
chase
the
cytotox
which
I'm
guessing
is
also
slightly
delayed,
but
we
can
keep
keep
asking.
E
I've
corresponded
with
them
and,
let's
see
so
I
emailed
renault
last
friday.
He
said
I'll
continue
working
on
your
compounds
next
week
when
alex
has
come
in
after
her
self-isolation,
so
they're
also
having
trophied
problems,
but
I
we
can
just
keep
it.
You
know
on
their
radar
and
I
think
they
are
planning
to
pick
it
up
soon.
Fine.
A
A
A
So
the
the
plan
is,
it
seems
like
quite
visible
this
month,
but
they
were
planning
to
do
this
in
february.
The
plan
is
that
they
are
going
to
do
that
scale
up
after
playing
around
with
a
few
different
conditions
and
and
send
us
the
crude
material
which
we
then
purify
and
characterize
by
nmr.
So
that's
the
deal
it's
they're,
gonna,
they're,
gonna
carry,
you
know,
carry
out
that
scale
up
for
us
and
then
we
do
everything
else
after
that
which
is
which
is
really
good.
A
So
I
mean
I
was
hoping
exactly
for
this,
that
they
found
something
that
was
looking
decent
and
should
allow
us
to
to
find
out
what
we've
got
two
monohydroxide
metabolites,
which
is
the
thing.
Those
are
the
things
that
we
get
through
from
then
that's
good.
I
mean
something
and
we'll
see
what
they
say.
Have
you.
E
A
Things
so
we
we
wait,
but
it's
good
that
they're
progressing
and
they're
still
active
in
the
lab,
which
is
correct
and
then
the
other
thing
which
is
the
I
guess.
The
main
item
for
us,
particularly
in
you
know
during
lockdown,
is
the
mechanism
of
action
stuff,
so
dana
posted
very
nice
analysis
of
which,
of
course,
I
can't
find
of
this
stuff
now,
which
I
will
pick
up
so
wait.
A
E
Okay,
so
this
paper
that
I
pulled
this
image
from
is
lee
is
an
author
on
it,
and
so
it's
not
it's
sort
of
specific
to
the
experiment
that
they
were
doing,
but
I
think
the
same
experimental
design.
So
they
have
the
beads
that
which
are
so.
They
have
kinase
inhibitors
that
are
immobilized
on
the
beads.
So
that's
basically
the
solid
phase.
Then
they
either
incubate
the
mrsa
cells
with
dmso
or
our
compounds,
so
we
sent
them
an
activity
inactive
so
they
did
both
of
those
and
then
so.
E
So
if
you
see
decreased
binding
in
the
presence
of
compound,
then
that's
an
indication
that
your
compound
is
out
competing
whatever
the
inhibitor
is
on
the
bead.
That
would
be
pulling
down
the
the
protein,
but
that's
the
most
straightforward
way
to
interpret
the
results.
I
think,
and
so
then
the
data
that
they
sent
us
was
basically
a
list
of
proteins,
I'm
not
sure
whether
they're
all
kinases
or
not,
but
anyway,
and
then
they've
calculated
this
log2
fold
change.
So
it's
relative
to
dmso
for
the
active
compound
and
the
inactive
one.
E
Yeah
yeah,
so
it's
it's
basically
a
proteomics
sort
of
profiling
experiment,
so
the
ones
with
a
negative
fold
change
mean
that
the
protein
is,
I
don't
know
less
abundant
in
the
presence
of
compounds
and
then
a
positive,
full
change
means
that
it's
more
abundant.
So
there
were
quite
a
few
with
a
positive
full
change.
So
one
of
the
questions
that
I
have
for
them
would
be
like.
What
exactly
would
the
mechanism
be
so
where
your
compound
would
be
increasing
the
amount
of
protein
that
would
be
pulled
down?
I
mean
I
guess.
E
A
E
E
E
I
think
it
is
because
there's
a
sheet
in
their
excel
document
that
has
the
species
in
there,
but
so
I
I
mean
that
would
be
just
nice
to
get
that
confirmed
by
them.
So
we're
not,
you
know,
wondering
a
bit
and
then
I
think
we
need
to
find
out.
You
know,
what's
known
about
these
targets
and
whether
it's
reasonable
to
expect
that
that
would
be
the
mechanism.
A
B
A
B
A
E
A
Because
I
I
guess
I
I'm
just-
I
know
that
the
group
that
works
there
at
unc
is
has
a
huge
amount
of
expertise
on
human
kinases.
So,
yes,
I'm
just
thinking
how
it
is.
Maybe
it's
by
analogy
I
don't
know
so
I
think
that's
gonna,
be
our
first
question.
Isn't
it
to
make
sure
that
we're
dealing
with
those,
then,
of
course
the
question
is
well
all
right.
If
we're
talking
about
mercer
targets,
then
what
are
we
gonna?
H
E
A
A
A
A
B
A
All
right,
but
we
ain't,
so
I
think
we
we
we
can.
We
can
answer
all
these
things
next
week
when
we
get
one
we
we
have
the
you
know
the
team
themselves
on
speed
dial,
so
we
can
just
get
them
in
and
they
can
explain
the
whole
thing
which
is
really
good,
and
I
just
so.
I
think
it's
given
the
number
of
potential
proteins
in
that
spreadsheet.
The
fact
that
there
are
this
small
number
of
those
that
are
relevant
is
quite
good
news
at
the
outset,
I'm
saying,
ultimately,
you
know
experimentally.
A
A
All
right-
and
I
think
so
I
think
all
the
other
things
were
again
just
actions
for
people
to
deal
with.
The
only
thing
I
was
just
gonna
highlight,
I
think,
was
the
the
molecule
donations
terms.
I
tweaked
a
little
bit
whilst
I
was
thinking
about
it
over
the
break
and
if
they're,
okay,
because
I
didn't
change
anything-
I
just
sort
of
grouped
them
differently
to
try
and
make
them
a
little
bit
easier
to
understand.
A
A
Great
all
right,
that's
great,
but
nothing
new
there,
just
just
a
different
way
of
expressing
it
and
then
the
rest
of
it
was
as
as
perc
as
a
bunch
of
action
which
we
haven't
done.
You
know
christmas
is
one
of
those
times
when
you
get
done
far
less
than
you
think
you're
gonna
get
done
even
in
a
long
day
on
christmas,
I
didn't
get
all
these
things
done.
So
was
there
anything
else?
Anyone
was
thinking
about
or
wanted
to
talk
about
before
we
wrap
up.
A
Oh,
this
guy
I
may
have
to
just
if
everyone
can
talk
amongst
themselves.
I
can
probably
do
this.
Well,
actually,
you
know
what
we
can
do
this
offline.
What
we
might
be
able
to
do
is
is
share
it
around
us
a
little
bit
and
then
have
a
think
about
it,
rather
than
you
yeah
watching
me
entertainingly
log
in
through
ecl's,
but
that's
great
you've
done
that.
So
that's
a
that's
an
item
we
can.
We
can
look
at
and
think
about
the
next
time,
just
conscious
people's
time.